The abstract is read at the publisher; the summary is JClub's.
In the global Enlighten EV-ICD Post Approval Registry (787 patients), 1-year freedom from major system- or procedure-related complications was 89.1%, with first appropriate therapy at 7.3%.
- Why it matters: Real-world performance of the Aurora EV-ICD system, including a novel sensing discriminator, is needed to confirm safety and therapy efficacy beyond premarket trials.
- What they did: A prospective registry enrolled 787 patients undergoing an EV-ICD implantation attempt; Kaplan-Meier estimated 1-year event rates, including major complications and first appropriate/inappropriate therapy.
- The result: At 1 year, shock success for discrete spontaneous episodes was 100% (61/61), antitachycardia pacing success was 74.2% for monomorphic ventricular tachycardia, and noncardiac oversensing caused 40.5% of inappropriate shocks.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.